Studies On New Mononuclear And Polynuclear Platinum Compounds With Trans-geometry
Funder
National Health and Medical Research Council
Funding Amount
$68,617.00
Summary
Even in post-genomic age cisplatin continues to be widely used as a highly successful anticancer drug. However, the drug has a number of side effects and does not show activity against many types of cancer. in some cases, resistant form of cancer develops for which the drug does not function. An example is ovarian cancer. This project aims to arrive at new platinum-based anticancer drugs targeted to ovarian cancer.
Designing Novel Apolipoprotein A1 Mimetic Peptides As Drug Treatment For Atherosclerosis
Funder
National Health and Medical Research Council
Funding Amount
$60,016.00
Summary
Cardiovascular disease is the formation of atherosclerotic plaques caused by the imbalance between the amount of cholesterol delivered and removed from the arteries. Apolipoprotein A-1 (ApoA-1) is the main protein of high density lipoprotein (HDL) and removes cholesterol out of cell. In this project we are aimed at designing and testing new drugs (ApoA1-mimetic peptides) which will elicit the same anti-atherogenic properties as apoA-1, as a therapeutic agent for prevention of atherosclerosis.
Advanced Anti-cancer Activities With Therapeutic Agents That Induce Tumor Cell Apoptosis And Antitumor Immune Responses.
Funder
National Health and Medical Research Council
Funding Amount
$85,701.00
Summary
The aim is to perform pre-clinical studies to identify new therapies for blood cancers. We will utilise three new anti-cancer agents that kill tumor cells and genetically engineered mice that develop cancer. We will determine if these three new agents kill the mouse tumor cells and activate anti-tumor immunity. The combined effect of killing blood cancer cells using new therapeutics, coupled with enhancing the anti-cancer immune response may hold the key to developing new treatments.
Development Of Small Molecule Isoform-Selective Dynamin Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$85,526.00
Summary
Dynamin has roles in nerve cell communication and in cell division. There are 3 dynamin genes: dynamin I in brain; dynamin II in all cells; and dynamin III in brain and testes. Determination of potential selectivity of small molecule dynamin inhibitors for each dynamin gene can provide a basis for the development of new antiepileptic drugs which are specific for dynamin I and thus neuronal tissues, as well as new anticancer drugs that target dynamin II in nonneuronal cells.
Drug Resistance In DNA Repair Defective Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$122,032.00
Summary
Ovarian cancer is a major cause of cancer death in women because current treatments are inadequate. Half of aggressive ovarian cancers have abnormalities in DNA repair and respond to new PARP inhibitor therapy, yet even then the cancer often recurs. I will use a new model to study human ovarian cancers in mice. My focus will be understanding resistance to PARP inhibitors in individual ovarian cancers and designing approaches to overcome this resistance.